These targets include genes known to represent receptors involved in NF-κB activation, such as TLR9 (LFC = 3.43; RS: 26.3% vs. CLL: 0.02%), CD40 (LFC = 0.62; RS: 43.6% vs. CLL: 22.4%), and MYD88 (LFC = 2.15; RS: 22.4% vs. CLL: 0.04%), in addition to the NF-κB components previously described (NFKB1, NFKB2, RELA, MAP3K14). This evidence concerns the gene MYD88 and B-cell chronic lymphocytic leukemia.